Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Allurion Technologies (ALURW) Long-Term Debt Repayments (2023)

Allurion Technologies posted quarterly Long-Term Debt Repayments of $8.2 million for Q4 2023, up 312.5% on a QoQ basis from $2.0 million in Q3 2023.

Allurion Technologies (ALURW) has 1 years of Long-Term Debt Repayments data on file, last reported at $8.2 million in Q4 2023.

  • For the quarter ending Q4 2023, Long-Term Debt Repayments changed N/A year-over-year to $8.2 million; the trailing twelve-month figure through Dec 2024 stood at $10.2 million (changed N/A YoY), and the FY2024 full-year result was $47.7 million, up 343.91% from the prior year.
  • Long-Term Debt Repayments for Q4 2023 stood at $8.2 million, up from $2.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $8.2 million in Q4 2023 and bottomed at $2.0 million in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Allurion Technologies - - 1.23 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 -8.25 Mn
Dec 31, 2023 -8.25 Mn
Sep 30, 2023 10.25 Mn
Sep 30, 2023 10.25 Mn